Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 8/20 | 0.46 |
| ▸ | CYP21A2 | P08686 | 7/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610905 | 1.00 | CYP17A1 (0.46) | CYP17A1CYP21A2CYP11B1MAPKAPK2CCNT1 | |
| SCHEMBL13442749 | 0.91 | CYP17A1 (0.46) | CYP17A1CYP21A2CYP11B1MAPKAPK2CCNT1 | |
| SCHEMBL3605831 | 0.88 | MAPKAPK2 (0.48) | MAPKAPK2CDK9TBK1MAPK1MAPT | |
| SCHEMBL3605830 | 0.88 | MAPKAPK2 (0.48) | MAPKAPK2CDK9TBK1MAPK1MAPT | |
| SCHEMBL13408082 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2CCNT1CDK9CYP3A4MAPK1 | |
| SCHEMBL3608148 | 0.85 | MAPKAPK2 (0.46) | MAPKAPK2TBK1MAPK1KDM4EALDH1A1 | |
| SCHEMBL3608151 | 0.85 | MAPKAPK2 (0.46) | MAPKAPK2TBK1MAPK1KDM4EALDH1A1 | |
| SCHEMBL3614881 | 0.85 | CYP17A1 (0.46) | CYP17A1CYP21A2CYP11B1MAPKAPK2CCNT1 | |
| SCHEMBL3614883 | 0.85 | CYP17A1 (0.46) | CYP17A1CYP21A2CYP11B1MAPKAPK2CCNT1 | |
| SCHEMBL3607124 | 0.84 | MAPKAPK2 (0.46) | MAPKAPK2CDK9TBK1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| CN-101516874-A | Pyrrole derivatives for the treatment of cytokine mediated diseases | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | claimed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| CN-101516874-A | Pyrrole derivatives for the treatment of cytokine mediated diseases | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | CYP17A1 149/4885CYP21A2 42/4885CYP11B1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.